Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Adult Patients with Bullous Pemphigoid
2024-510745-34-00Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Dupixent + standard corticosteroid therapy with Placebo + standard corticosteroid therapy (2 arms). Primary endpoint: Proportion of patients achieving sustained remission. Started Aug 2024; status: completed.
02
Drugs
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2024-510745-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510745-34-00.